Navigation Links
VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
Date:2/11/2008

- Companies Provide Update on Status of Integration Planning -

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN), a biopharmaceutical company, and Raven biotechnologies, inc. a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for treating cancer, announced today that VaxGen's registration statement on Form S-4 related to the proposed merger with Raven biotechnologies has been declared effective by the Securities and Exchange Commission. VaxGen expects to mail the related proxy statement/prospectus to stockholders on February 12. VaxGen's Board of Directors has set March 28th as the date for the Special Meeting of Stockholders to vote on the proposed transaction. Consistent with previous guidance, the date of record for this vote is January 31, 2008.

"We are very pleased to have completed the regulatory phase of this process, and are now on track for a stockholder vote and, I am confident, completion of the merger soon thereafter." Said James P. Panek, CEO and President of VaxGen.

Additionally, VaxGen and Raven have each made significant progress in the operational and planning activities necessary prior to the close of the merger and required to ensure momentum thereafter. This progress includes:

-- The implementation of a restructuring at Raven, resulting in a

reduction in headcount of 15 percent. VaxGen has also completed a

further modest headcount reduction. This positions the two companies

to meet the objective of a combined continuing headcount of

approximately 60, as stated in the announcement of the merger

agreement on November 12, 2007. Raven and VaxGen believe the

resources now in place position the companies to successfully pursue

the stated drug development and financial objectives of the merged

company. Raven continues to advance its near-
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
10. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
11. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... development of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has ... to commence in Europe. - ...
... 20 The MattsonJack Group, Inc.,(MattsonJack), is pleased ... M.P.H. to Medical Director for MattsonJack. (Photo: ... in September 2000 as a consultant and,Assistant Medical ... the,University of Missouri -- Kansas City. He subsequently ...
... The Chrome Group today announced its,plans to seek ... on trading,platforms in Europe and the Middle East. In ... Officer, Mr. Val Oji said that "this,was part of ... the next two years. Chrome recently signed a Memorandum,of ...
Cached Biology Technology:YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... DALLAS Nov. 16, 2009 As the number of ... "swine flu," continues to rise, researchers have been scrambling to ... lower than expected in older adults. In ... Proceedings of the National Academy of Sciences , a ...
... With 900,000 assisted reproduction treatments annually such as ... to screen both partners before each treatment could lead ... figures do not include the additional overhead costs such ... have to carry on top of that. The new ...
... been awarded nearly $3 million in federal stimulus funds ... Lindsay and Paul Westerhoff will lead a pair of ... fields of rapid DNA sequencing and the potential health ... & Reinvestment Act of 2009 ("Recovery Act" or "ARRA"), ...
Cached Biology News:UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 2UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 3Statement of ESHRE on the European Commission proposal of viral screening 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 3
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... Ideal for biocompatibility testing at ... circulation of air through a clean ... internal temperature up to 140F. Transparent ... strip shields allow easy access to ...
... Note: Protein determined by Biuret. ... M (NH 4 ) 2 ... Preparation Note: Affinity purified • ... • Additives: MgCl 2 1 ...
Biology Products: